The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text

Medicine, Oncology, Breast Oncology +7

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Differences in Breast Cancer Survival by Molecular Subtypes in the United States

Nadia Howlader, Kathleen A. Cronin, Allison W. Kurian et al. · Cancer Epidemiology Biomarkers & Prevention · 2018 · 604 citations

Medicine, Biostatistics, Oncology +14